Joshua Resnick - 05 Jun 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
AVTE
Transactions as of
05 Jun 2024
Transactions value $
$0
Form type
4
Filing time
07 Jun 2024, 18:00:16 UTC
Previous filing
28 May 2024
Next filing
21 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +12.5K $0.00 12.5K 05 Jun 2024 Common Stock 12.5K $18.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.